Growth and change of COVID-19 until 2030


The major players in the isothermal nucleic acid amplification (INAAT) technology market are Alere, Biomeriux, Qiagen and Becton, Dickinson and Company. The global isothermal nucleic acid amplification (INAAT) technology market is expected to grow by $ 2.

New York, September 28, 2021 (GLOBE NEWSWIRE) – announces the publication of the report “Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2021: COVID-19 Growth And Change To 2030” – https: / / www.
$ 36 billion in 2020 to $ 2.62 billion in 2021 at a compound annual growth rate (CAGR) of 11%. The growth is primarily driven by businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, the remote work and closure of business activities which resulted in operational challenges. The market is expected to reach $ 4.03 billion in 2025 at a CAGR of 11.4%.

The isothermal nucleic acid amplification technology (INAAT) market comprises the sale of isothermal nucleic acid amplification technologies and related services. The services include only the installation and maintenance services offered by the equipment manufacturers.

Isothermal nucleic acid amplification technologies are used to amplify the DNA sequence of two different nucleic acid segments at constant temperature.

The Isothermal Nucleic Acid Amplification (INAAT) Technology Market covered in this report is segmented by Product into Instrument, Reagent. It is also segmented by end user into hospitals, reference laboratories, others; by technology in NASBA, HAD and by application in blood screening, diagnosis of infectious diseases, cancer.

The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East & Africa.

The isothermal nucleic acid amplification technology market is strictly regulated by strict regulatory policies that govern the operation, approvals, and standards set for manufacturers in this market. These regulations discourage companies from investing in new products for research and development or from entering new markets.

For example, the US Food and Drug Administration (USFDA) requires multi-lab validation of loop-mediated isothermal amplification that takes twice as long as the European Regulatory Commission to review the process. Lengthy regulatory procedures delay the scope for further study of the safety and effectiveness of devices and affect the operating cycle of vendors, thereby negatively affecting the growth of the market.

Nanostructures are incorporated into in vitro diagnostics and in vitro rapid diagnostic assays (RDTs) to improve existing assays and make them more efficient or to create innovative diagnostic testing approaches that are incorporated into cutting edge applications on duty. Nanostructures / nanotechnologies use nanoparticles to enhance drug action in treatment and nanotechnology, there is a need to design, characterize, produce and apply devices, structures and systems through controlled manipulation of size and shape to the nanoscale.

For example, a range of RDTs have been developed to diagnose syphilis such as AccuBioTech (Accu-Tell Rapid Syphilis Test), Alere, Inc. (Alere Determine), Alere / Standard Diagnostics (SD Syphilis 3.0), The Tulip Group / Qualpro (Syphicheck – WB), Cypress Diagnostics (rapid syphilis test) and Omega Diagnostics (Visitect Syphilis). These RDTs allow patients to be diagnosed at the point of care (POC).

In 2018, Tecan, a provider of laboratory instruments and solutions, acquired Nugen Technologies for $ 54.5 million. The acquisition helps Tecan expand into a new market segment for Next Generation Sequencing Reagents (NGS). Nugen Technologies is a biotechnology company founded in 2000. The US-based company, headquartered in California, manufactures molecular biology reagents for next-generation sequencing genomic analysis.

The incidence of infectious diseases such as H. influenzae, S. pneumonia (respiratory tract infections), N. gonorrhoeae, C. trachomatis (genital infections) and tuberculosis is increasing and requires isothermal nucleic acid amplification technology. (INAAT) to diagnose them. For example, according to the World Health Organization, 17 million people die from infectious diseases each year. Another report from the Centers for Disease Control shows that the number of diseases caused by mosquitoes, ticks and fleas like West Nile disease, Zika, malaria and Lyme disease has tripled. Likewise, according to a survey by the NCBI, about 50% of the population in the United States (about 157 million) suffered from at least one chronic disease in 2020. The increase in infectious or chronic diseases is driving the demand for diagnosis. by isothermal. nucleic acid amplification technology.

The isothermal nucleic acid amplification technology market is regulated by government agencies such as the European Medicines Agency (EMA), USFDA (US Department of Food and Drugs), and others. For example, according to the USFDA, each medical device is classified into three groups which is Class 1, Class 2, and Class 3.

Class 1 devices require less regulatory control and Class 3 requires the most. However, devices that have not been marketed before, such as in the case of INAAT devices, will be classified as Class 3 devices in accordance with the amendment relating to medical devices.

Such devices require the approval of a Pre-Market Application (PMA) under federal law. Pre-market approval (PMA) is the FDA’s scientific and regulatory review process to assess the safety and efficacy of Class 3 medical devices.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, United Kingdom and United States.
Read the full report:

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Leave A Reply

Your email address will not be published.